Events & Presentations

Corporate Presentation

Corporate Presentation - February/March 2026

February 26, 2026

Triple Meeting 2025: Preliminary Phase 1 Safety and Antitumor Activity of XmAb819, a First-in-Class ENPP3 x CD3 Bispecific Antibody, in Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

October 24, 2025

ECCO 2025: Phase 1/2 Study to Assess Safety, Tolerability, and Efficacy of XmAb942 (anti-TL1A) in Healthy Participants and Participants With Ulcerative Colitis

February 19, 2025

ASH 2024: Plamotamab: First Presentation of Subcutaneous Administration in a Phase 1 Dose-Escalation Study in Heavily Pretreated R/R NHL Patients Who Had Prior CAR-T Cell Therapy

December 9, 2024

UEGW 2024: Discovery and Characterization of a Novel High-Affinity Anti-TL1A Monoclonal Antibody with Extended Half-life for the Treatment of Inflammatory Bowel Disease

October 10, 2024

SITC 2023: A phase 1, first-in-human, open-label, dose-finding and expansion study of XmAb808, a B7H3 x CD28 bispecific antibody, in combination with pembrolizumab in patients with advanced solid tumors

November 3, 2023

AACR 2023: Tumor-specific CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors

April 17, 2023

ASH 2022: A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Non-Hodgkin’s Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis

December 12, 2022

A Phase 1, Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Patients With Relapsed or Refractory Clear Cell Renal Cell Carcinoma

November 10, 2022

Phase 1 Safety and Anti-tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed/Refractory Non-Hodgkin’s Lymphoma

December 12, 2021

Bispecific claudin-6 x CD3 antibodies in a 2+1 format demonstrate selectivity and activity on human ovarian cancer cells

April 10, 2021

Tumor-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors

November 9, 2020

AACR 2020: XmAb30819, an XmAb® 2+1 ENPP3 x CD3 bispecific antibody for RCC, demonstrates safety and efficacy in in vivo preclinical studies

June 22, 2020

ASH 2019: Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with R/R NHL and CLL

December 9, 2019

Festival of Biologics USA 2019: Tumor selective cytotoxicity by TAA x CD3 bispecifics utilizing a 2:1 mixed-valency format

March 4, 2019

American Society of Hematology 2014 Annual Meeting Poster: XmAb Anti-CD20 × Anti-CD3 Bispecific Antibodies in B-cell Lymphomas and Leukemia Chu, et al, Abstract ID# 3111

December 7, 2014

Events

Barclays 28th Annual Global Healthcare Conference

Mar 11, 2026 at 11:30 AM EDT

Listen to webcast

Leerink Partners 2026 Global Healthcare Conference

Mar 10, 2026 at 10:00 AM EDT

Listen to webcast

TD Cowen 46th Annual Health Care Conference

Mar 02, 2026 at 3:50 PM EST

Listen to webcast

Piper Sandler 37th Annual Healthcare Conference

Dec 02, 2025 at 2:00 PM EST

Listen to webcast

TD Cowen Immunology and Inflammation Virtual Summit

Nov 12, 2025 at 3:00 PM EST

Listen to webcast

Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

Oct 24, 2025 at 1:30 PM EDT

Listen to webcast

Supporting Materials

View Presentation 2 MB

Scientific Presentations

Triple Meeting 2025: Preliminary Phase 1 Safety and Antitumor Activity of XmAb819, a First-in-Class ENPP3 x CD3 Bispecific Antibody, in Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

October 24, 2025

ECCO 2025: Phase 1/2 Study to Assess Safety, Tolerability, and Efficacy of XmAb942 (anti-TL1A) in Healthy Participants and Participants With Ulcerative Colitis

February 19, 2025

ASH 2024: Plamotamab: First Presentation of Subcutaneous Administration in a Phase 1 Dose-Escalation Study in Heavily Pretreated R/R NHL Patients Who Had Prior CAR-T Cell Therapy

December 9, 2024

UEGW 2024: Discovery and Characterization of a Novel High-Affinity Anti-TL1A Monoclonal Antibody with Extended Half-life for the Treatment of Inflammatory Bowel Disease

October 10, 2024

November 3, 2023

AACR 2023: Tumor-specific CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors

April 17, 2023

December 12, 2022

A Phase 1, Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Patients With Relapsed or Refractory Clear Cell Renal Cell Carcinoma

November 10, 2022

Phase 1 Safety and Anti-tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed/Refractory Non-Hodgkin’s Lymphoma

December 12, 2021

Bispecific claudin-6 x CD3 antibodies in a 2+1 format demonstrate selectivity and activity on human ovarian cancer cells

April 10, 2021

Tumor-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors

November 9, 2020

AACR 2020: XmAb30819, an XmAb® 2+1 ENPP3 x CD3 bispecific antibody for RCC, demonstrates safety and efficacy in in vivo preclinical studies

June 22, 2020

ASH 2019: Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with R/R NHL and CLL

December 9, 2019

Festival of Biologics USA 2019: Tumor selective cytotoxicity by TAA x CD3 bispecifics utilizing a 2:1 mixed-valency format

March 4, 2019

American Society of Hematology 2014 Annual Meeting Poster: XmAb Anti-CD20 × Anti-CD3 Bispecific Antibodies in B-cell Lymphomas and Leukemia Chu, et al, Abstract ID# 3111

December 7, 2014

Tools

Events & Presentations